Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021, at 3:00 p.m. Eastern Time.
ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.
Acadia (ACAD) delivered earnings and revenue surprises of 10.00% and -9.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported a loss of $43.9 million in its second quarter.
--- Fiscal year 2021 revenue guidance reduced to $480 to $515 million
--- Pimavanserin met the secondary endpoint of significantly reducing trial discontinuation for any reason by 2.2 fold
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the U.S. financial markets. Acadia's...
Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.
Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.